Rituximab in Progressive Immunoglobulin A (IgA) Nephropathy
Status:
Completed
Trial end date:
2015-09-01
Target enrollment:
Participant gender:
Summary
This study was about IgA nephropathy, a form of kidney disease characterized by the presence
of blood and protein in the urine. This study was done to determine if the medication
rituximab could reduce protein in the patient's urine.
Hypothesis: In patients with progressive IgA nephropathy an intravenous infusion of 1000 mg
of rituximab on Day 1 and Day 15 and Days 168 and 182 is superior to conventional therapy in
reducing 24 hour proteinuria, and slowing progression of chronic kidney disease.
Phase:
Phase 4
Details
Lead Sponsor:
Mayo Clinic
Collaborators:
Biogen Columbia University Genentech, Inc. Ohio State University Stanford University University of North Carolina, Chapel Hill